Design Therapeutics, Inc.
Design Therapeutics, Inc. (DSGN) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · DSGN · as of Sep 30, 2025
Ownership Breakdown
94
Institutional Holders
▲ 2 vs Q2
$259.73M
Total Inst. Value
▲ $143.36M vs Q2
62.46M
Shares Outstanding
freeFloat 56.62%
34.49M
13F Shares Held
▼ 37,880 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
DSGN largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
SR ONE CAPITAL MANAGEMENT, LP pharmaceutical preparations | 6.53M | 11.48% | 11.48% | $49.14B | Nov 12, 2025 | — held |
LOGOS GLOBAL MANAGEMENT LP pharmaceutical preparations | 3.65M | 6.43% | 6.43% | $27.52B | Nov 14, 2025 | ▼ 562.6K |
POINT72 ASSET MANAGEMENT, L.P. pharmaceutical preparations | 3.34M | 5.88% | 5.88% | $25.15B | Nov 14, 2025 | ▲ 1.53M |
BLACKROCK, INC. pharmaceutical preparations | 2.04M | 3.60% | 3.60% | $15.39B | Nov 12, 2025 | ▼ 351.4K |
FRAZIER LIFE SCIENCES MANAGEMENT, L.P. pharmaceutical preparations | 1.95M | 3.44% | 3.44% | $14.71B | Nov 14, 2025 | — held |
TANG CAPITAL MANAGEMENT LLC pharmaceutical preparations | 1.78M | 3.13% | 3.13% | $13.41B | Nov 14, 2025 | — held |
BAKER BROS. ADVISORS LP pharmaceutical preparations | 1.71M | 3.01% | 3.01% | $12.90B | Nov 14, 2025 | — held |
ALMITAS CAPITAL LLC pharmaceutical preparations | 1.53M | 2.69% | 2.69% | $11.52B | Nov 17, 2025 | — held |
VANGUARD GROUP INC pharmaceutical preparations | 1.44M | 2.54% | 2.54% | $10.87B | Nov 7, 2025 | ▼ 27.9K |
DRIEHAUS CAPITAL MANAGEMENT LLC pharmaceutical preparations | 1.08M | 1.89% | 1.89% | $8.10B | Nov 14, 2025 | — held |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
10
Increased
+1.77M shares4
New Positions
first time holders24
Decreased
−2.11M shares0
Sold Out
fully exitedNet shares change (top 50)
345.6K
+1.77M / −2.11M
Net new holders
-10
4 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
DSGN insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
7
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Shapiro David director | Mar 31, 2026 | Award | 60,000 | $10.64 | $638.4K | 60.0K | Form 4 ↗ |
Shapiro David director | Mar 31, 2026 | Award | 7,500 | $10.64 | $79.8K | 7.5K | Form 4 ↗ |
Storgard Chris Chief Medical Officer | Jan 2, 2026 | Award | 250,000 | $9.10 | $2.27M | 250.0K | Form 4 ↗ |
Jeffries Sean Chief Operating Officer | Jan 2, 2026 | Award | 375,000 | $9.10 | $3.41M | 375.0K | Form 4 ↗ |
Burgess Julie Chief Accounting Officer | Jan 2, 2026 | Award | 150,000 | $9.10 | $1.36M | 150.0K | Form 4 ↗ |
Gover Justin D. director | Jan 2, 2026 | Award | 45,000 | $9.10 | $409.5K | 45.0K | Form 4 ↗ |
Shah Pratik President, CEO and Chairperson | Jan 2, 2026 | Award | 750,000 | $9.10 | $6.83M | 750.0K | Form 4 ↗ |
Shah Pratik President, CEO and Chairperson | Dec 9, 2025 | Award | 525,000 | $2.48 | $1.30M | 525.0K | Form 4 ↗ |
Gover Justin D. director | Sep 9, 2025 | Award | 30,000 | $6.64 | $199.2K | 30.0K | Form 4 ↗ |
Gover Justin D. director | Sep 9, 2025 | Award | 15,833 | $6.64 | $105.1K | 15.8K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Design Therapeutics, Inc. (DSGN) is primarily owned by institutional investors, who hold approximately 55.2% of total shares outstanding. Company insiders own approximately 43.38%, while retail and public investors account for the remaining 1.39%.
The largest institutional shareholder of Design Therapeutics, Inc. is SR ONE CAPITAL MANAGEMENT, LP, holding approximately 6.53 million shares — equal to 11.48% of outstanding shares — as of September 30, 2025.
A total of 94 institutional investors currently hold DSGN stock, with a combined institutional value of approximately $259,728,206 as of the most recent 13F filing period.
Frequently asked questions
DSGN ownershipDesign Therapeutics, Inc. (DSGN) is primarily owned by institutional investors, who hold approximately 55.2% of shares. The largest shareholder is SR ONE CAPITAL MANAGEMENT, LP with a 11.48% stake. Company insiders hold 43.38%. Data sourced from SEC Form 13F as of September 30, 2025.